Basic Gravol Information

• INN (International Nonproprietary Name): Cinnarizine
• Brand Names Available In Canada (English): Stugeron, Cinnarizine (25 mg tab, non-Rx)
• ATC Code: N07CA02 — calcium channel blocker for vestibular disorders (nervous system, other nervous system drugs)
• Forms & Dosages: Oral tablet 25 mg most common; extended-release tablets rare; syrup/suspension available in select regions
• Manufacturers In Canada (English): Multiple local generic suppliers and importers; original brand owner Janssen Pharmaceuticals; also STADA, Hasco, Biogaran, LEK, Gedeon Richter noted internationally
• Registration Status In Canada (English): Sold online/offline; status varies by province — check product DIN and provincial rules
• OTC / Rx Classification: Mostly OTC in many markets; in Canada classification can vary by province and distributor

Availability & Price Landscape

Major National Pharmacy Chains (Shoppers Drug Mart, Rexall, London Drugs)

Shoppers Drug Mart, Rexall and London Drugs commonly stock Stugeron or generic cinnarizine 25 mg, though exact in‑store availability varies by location and province.

Some chains list the product online while others keep it behind the counter or only by special order, so calling ahead is advisable.

Regional chains such as Jean Coutu and Pharmasave may also carry branded or generic packs, sometimes in limited blister sizes.

Stock levels fluctuate with travel seasons and local demand for vertigo treatment, especially before summer holidays and winter travel peaks.

Pharmacy staff can often check DINs and product origins before ordering for a customer.

Online Pharmacy Trends In Canada (Including Provincial Restrictions)

Online Canadian pharmacies increasingly list Stugeron and cinnarizine 25 mg for purchase, with vendor notices about province-specific sale rules.

Some provinces treat cinnarizine more tightly and require pharmacist consultation or place the product behind the counter.

Sellers often flag shipping restrictions where importation or provincial policy limits OTC sale without pharmacist assessment.

In our online pharmacy, gravol is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

When buying online, verify the Drug Identification Number (DIN) and the vendor’s Canadian licence to ensure the product is legitimate and compliant.

Price Ranges By Package Size (With Provincial Differences)

Typical retail pricing for cinnarizine in Canada ranges from about CAD $8 to $25 for small blister packs (10–30 tablets), depending on brand and province.

Larger bottles (around 100 tablets) usually offer a lower per‑tablet cost and better value for chronic users.

Online retailers sometimes undercut in‑store prices but consider shipping and any pharmacist consultation fees when comparing total cost.

Cross‑border buying from U.S. sellers happens, but check Health Canada DIN equivalence and import limits to avoid delays or non‑equivalent products at customs.

Always verify DINs listed on SKU pages; provincial formularies may differ in terms of how OTC vs prescribed packs are treated for coverage or sale.

Canadian Patient Insights & Satisfaction Levels

Forum And Review Platforms (Reddit Canada, HealthBoards, AskDocs)

Canadian users discuss Stugeron on Reddit Canada, HealthBoards and other forums, sharing experiences with motion sickness and vertigo care.

Common threads include first‑hand tips on timing doses before travel and pharmacy experiences around provincial sale requirements.

Posts also compare cinnarizine to Gravol (dimenhydrinate), meclizine and promethazine for sedation and effectiveness.

Pharmacists often appear in threads answering questions about interactions, DIN checks and provincial coverage.

Reported Benefits And Challenges From Canadian Patients

Users commonly report rapid relief for motion sickness and reduced vertigo episodes with 25 mg cinnarizine taken before travel.

Positive themes include predictable sedative effects that help with travel‑related nausea for short journeys.

Challenges reported include daytime drowsiness that affects driving or work performance and variable response in severe vestibular disorders.

Community posts express concern about long‑term use, mentioning weight gain and persistent fatigue after prolonged courses.

Several anecdotal safety signals describe extrapyramidal symptoms after extended use, particularly in older adults, prompting many to seek alternatives like Gravol or meclizine.

• Sentiment Summary: Mostly positive for short‑term motion sickness; cautious for long‑term use.
• Sample Anonymous Comments: "25 mg calmed my seasickness quickly but made me sleepy for hours."
• Sample Anonymous Comments: "Worked well for a ferry trip, pharmacist advised not to drive after dosing."

Product Overview & Brand Variants

INN And Brand Names Used In Canada

The International Nonproprietary Name (INN) is cinnarizine, commonly marketed in Canada as Stugeron 25 mg tablets or generics labelled Cinnarizine 25 mg.

Packaging often mirrors international formats: blister packs of 10–50 tablets or bulk boxes of 100 where available.

Local labelling appears in English and French as Stugeron or Cinnarizine (comprimé 25 mg) depending on the supplier and province.

Legal Classification Under Health Canada

Legal classification in Canada can vary by province and distributor, with many markets treating cinnarizine as non‑prescription for motion sickness but with differing sale requirements.

Always check the product Drug Identification Number (DIN) and the product monograph for the legally registered indications and dosing.

For product pages, display brand names, strengths, pack sizes and DIN where available, and advise customers to confirm local store availability before purchase.

Indications In Local Canadian Medical Practice

Approved Uses (Health Canada DIN Context)

Cinnarizine is primarily used for motion sickness and vestibular vertigo, and for some cerebral/peripheral circulatory disturbances where appropriate.

Dosing and official indications should be cross‑checked against the product DIN and the Health Canada product monograph for the exact marketed status.

Pharmacists commonly advise a single 25 mg dose two hours before travel for motion sickness prevention.

For vestibular disorders, clinicians may use 25 mg three times daily (up to 75 mg/day) under supervision and with monitoring.

Off-Label Patterns In Canadian Healthcare

Off‑label use includes adjunctive treatment for chronic vestibular dysfunction, refractory vertigo syndromes and selected specialist uses to support cerebral microcirculation.

Off‑label prescribing is typically documented with clinical rationale and follow‑up, and provincial formularies rarely reimburse OTC packs without a prescription displaying a DIN.

Motion Sickness

25 mg, 2 hours before travel — reimbursement: unlikely unless prescribed with DIN

Vestibular Vertigo

25 mg three times daily — reimbursement: variable; specialist prescription may be needed for coverage

Cerebrovascular/Peripheral Circulation

25 mg two to three times daily — reimbursement: case‑by‑case via formulary rules

How It Works In The Body

Layman’s Explanation (Canadian Patient-Friendly Tone)

Cinnarizine calms the inner‑ear balance system so that signals causing dizziness and nausea are reduced.

People often describe it as "calming the balance nerves" which helps stop motion‑related nausea before it starts.

The effect can also mildly relax small blood vessels in the brain, improving microcirculation in some patients.

Onset for motion sickness prevention is typically within one to two hours after a 25 mg dose.

Common counselling points include warning about sedation and advising patients not to drive until they know how it affects them.

Clinical Detail From Health Canada Resources

Clinically, cinnarizine is classified under ATC N07CA02 and acts on vestibular hair cells and cerebral microcirculation as a calcium‑channel blocker for vestibular disorders.

The drug has central and peripheral antivertiginous properties that reduce vestibular input to brainstem centres.

Hepatic metabolism is the main clearance route, with CYP2D6 implicated; therefore drug–drug interactions and liver impairment require caution.

Pharmacists should screen for interacting CYP2D6 substrates and advise on dose adjustments in hepatic dysfunction where noted in the monograph.

Dosage & Administration

Standard Regimens Per Canadian Guidelines

For motion sickness prevention, the standard adult dose is 25 mg taken about two hours before travel, repeating every eight hours if needed.

For treatment of vertigo or vestibular disorders, a common regimen is 25 mg three times daily, up to a maximum of 75 mg per day under supervision.

For missed doses patients should take the dose when remembered unless the next dose is imminent; do not double doses.

In case of overdose the patient may experience severe drowsiness, confusion or seizures and should seek emergency care.

Adjustments By Patient Type (With Canadian Clinical Notes)

Children under five years are not recommended to use cinnarizine, while ages five to twelve may use 12.5 mg two to three times daily if appropriate.

Elderly patients should receive the lowest effective dose with monitoring for sedation, confusion and parkinsonian signs.

Patients with hepatic impairment may need dose reduction given hepatic metabolism; consult the product monograph for specifics.

Pharmacists should document DIN and dosing on the patient record for monitoring and adverse‑event reporting where required.

Contraindications & Side Effects

Common (Health Canada-Approved List)

Absolute contraindications include known allergy to cinnarizine or excipients, porphyria, severe hepatic impairment, and pregnancy or breastfeeding unless strictly necessary.

Relative contraindications where caution is required include Parkinson’s disease, elderly patients, and concurrent use of CNS depressants or alcohol.

Common side effects include drowsiness, dry mouth, mild gastrointestinal upset, headache and fatigue.

Advise patients that mild weight gain may occur with prolonged use and that sedation can impact driving or operating machinery.

Rare But Serious (With Canadian Pharmacovigilance Data)

Rare but serious events include extrapyramidal symptoms and drug‑induced parkinsonism, which have been reported internationally and in Canadian vigilance summaries.

Severe hepatic reactions and seizures in the context of overdose are additional rare but serious risks.

Patients should stop the drug and seek prompt medical review for new involuntary movements, stiffness, tremor or persistent changes in mobility.

Pharmacovigilance reporting to Health Canada is recommended for suspected serious adverse events; record DIN and batch where possible.

Comparable Medicines In Canada

Alternatives Table (With DIN References)

Pros And Cons List

• Cinnarizine (Stugeron): Reliable for motion sickness and vestibular vertigo; main drawback is sedation and long‑term extrapyramidal risk in older adults.
• Dimenhydrinate (Gravol): Fast acting and widely available but causes drowsiness and anticholinergic effects.
• Meclizine: Longer duration and possibly less sedation for some; availability and DIN status may vary by product.
• Promethazine: Effective antiemetic for severe cases but stronger sedation and Rx requirement limit routine use for travel.

Current Research & Trends

Major Canadian Or International Studies 2022–2025

Recent studies have compared cinnarizine to dimenhydrinate and meclizine for short‑term motion sickness, showing similar immediate efficacy but different side‑effect profiles.

Research from 2022–2025 highlights increased scrutiny of long‑term extrapyramidal risk, especially in elderly cohorts, prompting recommendations to limit prolonged courses.

Comparative effectiveness work shows cinnarizine provides predictable antivertiginous benefit for many patients while clinicians weigh sedation risk against symptom control.

Investigations into adjunctive use for refractory vestibular migraine and chronic vestibulopathy are ongoing, with emphasis on patient‑reported outcomes in community pharmacy settings.

For practice implications: limit prolonged use in older adults, prioritise follow‑up, and consider alternatives when parkinsonism risk is present.

Common Patient Questions In Canada

(Include Concise Q&A List Focused On Canadian Context)

Can I drive after taking Stugeron?

No. Sedation is common; avoid driving or operating heavy machinery until you know how the drug affects you.

Is it covered by provincial drug plans?

Rarely for OTC packs; coverage may be possible if prescribed with a DIN and if listed on a specific formulary such as ODB, PharmaCare or RAMQ.

Can I take with Gravol (dimenhydrinate)?

Consult a pharmacist before combining CNS depressants as this increases sedation and anticholinergic burden.

Pregnancy or breastfeeding?

Generally avoid unless a specialist advises otherwise; discuss risks with your healthcare provider.

Can I buy online from a U.S. site?

Be cautious; check DIN equivalence, import limits and product authenticity before ordering across the border.

• Pharmacy Consultation Checklist: bring full medication list, age, pregnancy status, and symptoms to your pharmacist.

Regulatory Status

Health Canada Approval Process

Every marketed drug in Canada carries a Drug Identification Number (DIN) indicating Health Canada has assessed safety, efficacy and quality for that formulation.

Use the DIN to confirm the approved formulation and indications, and to check the product monograph for binding legal information.

Importers and online vendors must comply with Health Canada importation rules; verify that online pharmacies are licensed in Canada before purchasing.

DIN Number Relevance

Display the DIN prominently on product pages to help customers and providers verify the marketed indication and dosing instructions.

Provincial drug plans commonly require a DIN on a prescription to process reimbursement, so OTC purchases without a DIN on a prescription are seldom covered.

Pharmacy staff should maintain a short regulatory checklist for product sourcing, DIN verification and adverse‑event reporting procedures.

Visual Recommendations

Infographic Ideas For Canadian Context

Design 1: A "When To Take It" timeline showing a 2‑hour pre‑travel dose and 8‑hour repeat intervals.

Design 2: Side‑effect icons for sedation, dry mouth and movement disorder warnings, colour coded by urgency.

Design 3: A provincial map overlay indicating likely OTC vs prescription tendencies and examples of chain availability such as Shoppers, Rexall, Jean Coutu and London Drugs.

Design 4: A comparison chart contrasting Stugeron, Gravol (dimenhydrinate) and meclizine on onset, duration, sedation and age‑appropriateness.

Include bilingual (EN/FR) labels, clear DIN callouts on packaging photos, and accessible alt text for every visual element.

Buying & Storage Advice

In-Store Vs. Online Canadian Purchase Tips

Buy from licensed Canadian pharmacies, whether in‑store chains or verified online vendors, and confirm the DIN and expiry date before completing a purchase.

Ask the pharmacist about interactions with current prescriptions and whether provincial rules require pharmacist consultation for sale.

Cross‑border purchases are common but may involve customs delays and non‑equivalence risks; always verify product origin and DIN before importing.

Compare in‑store convenience versus online per‑tablet savings once shipping and verification fees are included.

Proper Storage With Canadian Climate Considerations

Store cinnarizine at room temperature in a cool, dry place away from sunlight and moisture, and keep it in the original packaging.

Avoid leaving tablets in cars where extreme cold in winter or heat in summer can damage the product.

For travel, carry tablets in original packaging with DIN visible and bring a pharmacist note or prescription if crossing borders or if flight crew requests documentation.

• Travel Checklist: original packaging, current medication list, prescription note (if applicable), and proof of purchase for discretionary screening.

Guidelines For Proper Use

Canadian Doctor/Pharmacist Advice Style

Confirm the indication first: motion sickness prevention or treatment of vestibular vertigo, and obtain a focused history including Parkinson’s disease, liver disease and pregnancy status.

Recommend the lowest effective dose: 25 mg two hours before travel for motion sickness, or 25 mg three times daily for short courses of vertigo treatment under supervision.

Warn about sedation: advise no driving or operating heavy machinery until the patient is sure of effects, and recommend avoiding alcohol.

Review concomitant CNS depressants and CYP2D6 substrates, and adjust therapy if interaction risk is identified.

For elderly patients or those who develop movement symptoms schedule follow‑up and consider alternative agents.

Document DIN and batch number for monitoring and report suspected adverse events to Health Canada per local pharmacovigilance procedures.

Delivery Across Canada (English)